UNSPSC 51112006: Pazopanib

This classification denotes a tyrosine kinase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7RN5DR86CK. European Medicines Agency schedules Pazopanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29175. Pazopanib generally arises in the molecular formula C21H23N7O2S. The term PAZOPANIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56.) As of Q4 2014, PAZOPANIB remains the US FDA Preferred Term for this commodity.

Pazopanib bears US NLM identifiers UMLS ID C1831796 and NCI Concept Code C74547. SMILES: CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.

UNSPSC 51112006 Pazopanib is a Commodity code covering a specific oncology pharmaceutical product. State and local governments procure pazopanib through cooperative purchasing vehicles that bundle it with broader generic pharmaceutical and OTC product portfolios. The work involves securing supply agreements with manufacturers or authorized distributors who can deliver the product through established wholesaler networks to public healthcare facilities, correctional systems, and other state and local health agencies. Issuing bodies are primarily multistate cooperative purchasing alliances administering contracts on behalf of participating state departments, counties, and municipal health systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with a response deadline of March 26, 2026. This procurement encompasses pazopanib alongside hundreds of other pharmaceutical products and requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026. Vendors must comply with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers, and accept a 3 percent administrative fee on all contract purchases. The RFP weights price competitiveness at 75 percent of the evaluation score, with the remaining 25 percent distributed across fixed pricing format compliance (10 percent), administrative data requirements (5 percent), EDI capability (5 percent), and agreement to the administrative fee structure (5 percent). MMCAP participates include Oregon and other states, and the contract term runs two years for new responders with optional extensions at MMCAP's discretion.